A forthcoming documentary from the LDN Research Trust gives compounding pharmacists, physicians and prescribers an opportunity to learn about a group of complex and debilitating syndromes that affect one in six Americans — syndromes that occur in almost every part of the body, often accompany each other and collectively exacerbate the patient’s pain and other symptoms. This article briefly summarizes these syndromes and their overlapping symptoms and discusses how you can help educate providers in your community — as well as your staff and patients — about their effects, along with the potential use of low-dose naltrexone (LDN) in compounding preparations.

Individuals who suffer from symptoms of gastrointestinal, autoimmune, dermatological and pain conditions make up 80% of the patient population. But here’s the good news: multiple studies indicate that low-dose naltrexone (LDN) may potentially help many of these conditions. Take a sneak peek at topics our Clinical Services team will discuss during the Low-Dose Naltrexone One-Day Virtual Conference on Thursday, November 21, 2024.

June is National Migraine and Headache Awareness Month and we want you to be well equipped to care for your migraine and headache patients.

Beau Harger explains why permeation-enhancing topical compounds are important options for many patients with acute or chronic pain. He also walks through the evolution of compounding bases used in this clinical area.

Bryan Prescott explains the most common needs of hospice patients and also provides potential treatment options that compounders can offer to help them. "Compounding pharmacies can play a vital role in the care of these patients," he says.

Tricia Heitman of PCCA's Clinical Services Team discusses compounded treatment options for women suffering from atropic vaginitis, vluvar lichen sclerosis, desquamative inflammatory vaginitis, vaginismus, high-tone pelvic floor dysfunction and vulvodynia.

Nat Jones of PCCA's Clinical Services Team discusses the clinical data about the efficacy of Permeation-enhanced topical pain therapy (PETPT) or transdermal pain therapy. He provides a brief history of transdermal pain therapy and evidence of the levels of efficacy PETPT has within medicine.

For patients looking for migraine relief, who once used the now discontinued Midrin for migraine treatment, there are compounding options from compounding pharmacies that can personalize severe headache medications. PCCA is here to talk about options that patients have, through the help of their local compounders.

The experts in our Clinical Services and Formulation Development departments recommend Lipoderm as a first choice for customized transdermal medications. Here’s why.

Late last year, we were excited to debut PermE8™ Anhydrous Gel, a new compounding base that holds a lot of potential for compounding pharmacies and their patients, especially when it comes to pain management.